Clinical trials: acne
Acne Vulgaris
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that : CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects CD0271…
- Trial name
- NCT01880320
- Testing
- CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
- Where
- 31 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Galderma R&D
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA
Acne Vulgaris
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
- Trial name
- DUAL (NCT04451330)
- Testing
- Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02566369
- Testing
- CD5789 (trifarotene) 50μg/g cream
- Where
- 124 sites in United States, Canada and 3 more
- Volunteers
- 1,208 people
- Sponsor
- Galderma R&D
Acne Scarring of the Face
Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to facial acne scars.
- Trial name
- NCT00642642
- Testing
- Autologous Human Fibroblasts (azficel-T)
- Where
- 7 sites in United States
- Volunteers
- 122 people
- Sponsor
- Castle Creek Biosciences, LLC.
Acne Vulgaris
A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
The goal of this study is to evaluate a complete topical acne regimen consisting of a prescription acne medication (Epiduo® Gel) and an acne-specific cleanser (Cetaphil® DermaControl™ Foam Wash) and moisturizer with sunscreen…
- Trial name
- NCT02249104
- Testing
- Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne
The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe…
- Trial name
- NCT00706433
- Testing
- aminolevulinic acid HCL (ALA), Vehicle (VEH)
- Where
- 14 sites in United States
- Volunteers
- 266 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Acne Vulgaris
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
- Trial name
- NCT03168321
- Testing
- IDP-123 Lotion, IDP-123 Vehicle Lotion
- Where
- 45 sites in United States, Canada
- Volunteers
- 813 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.
This study will compare two different acne treatments for the treatment of acne. Half of the participants will receive two marketed acne products (cleanser and leave-on topical treatment), while the other half of the participants…
- Trial name
- TIGER (NCT02698436)
- Testing
- Acne Mask, 2.5% Benzoyl Peroxide Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Acne Vulgaris
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl…
- Trial name
- NCT00926367
- Testing
- Clindamycin and benzoyl peroxide, benzoyl peroxide 2.5% and adapalene 0.1% gel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in…
- Trial name
- NCT06336603
- Testing
- Winlevi (clascoterone) 1% & Adapalene 0.3% gel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne, Scar
Fractional Resurfacing Device for Treatment of Acne Scarring
The purpose of this research study is to evaluate the safety and effectiveness of a new investigational laser device for treatment of acne scarring, for improvement in the appearance of surface texture and topography (recessed or…
- Trial name
- NCT00585286
- Testing
- 10,600 nm fractional carbon dioxide laser system
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Shoulder Infection
Skin Prep to Reduce Postoperative Shoulder Infection
Propionibacterium acnes is the most common pathogen identified from a surgical site infection in the shoulder. Standard skin preps do not prevent this type of infection.
- Trial name
- NCT02510144
- Testing
- Skin Prep Chlorhexidine, Skin Prep Benzoyl Peroxide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Maryland, Baltimore
Acne Vulgaris
Safety and Efficacy of the Use of Botox on Acne
To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)
- Trial name
- NCT00765375
- Testing
- Botulinum Neurotoxin Type A, Bacteriostatic saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- DeNova Research
Atrophic Acne Scar
Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
The purpose of this study is to determine whether Artefill is safe and effective for the correction of atrophic facial acne scars.
- Trial name
- NCT01559922
- Testing
- Normal Saline, Artefill
- Where
- 10 sites in United States
- Volunteers
- 175 people
- Sponsor
- Suneva Medical, Inc.
Acne Vulgaris
Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne
The objectives of this clinical trial are to compare the quality of life of the subjects, the efficacy and the tolerance of Duac® Gel (gel formulation with a combination of clindamycin phosphate [equivalent to 1% clindamycin] and…
- Trial name
- NCT00807014
- Testing
- Duac Gel, Differin gel
- Where
- 8 sites in Spain
- Volunteers
- 169 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe…
- Trial name
- NCT02575950
- Testing
- LEO43204
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- LEO Pharma
Acne Vulgaris
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or…
- Trial name
- NCT01706250
- Testing
- MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- Volunteers
- 20 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily.
- Trial name
- NCT03341910
- Testing
- DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Acne Vulgaris
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
- Trial name
- NCT03271021
- Testing
- FMX101, Vehicle Foam
- Where
- 98 sites in United States
- Volunteers
- 1,488 people
- Sponsor
- Vyne Therapeutics Inc.